Related Experiment Video
Updated: Jan 20, 2026

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
Published on: January 3, 2025
Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced
Andrew R Haas1, Janos L Tanyi2, Mark H O'Hara3
1Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Abstract:
This phase I study investigated the safety and activity of lentiviral-transduced chimeric antigen receptor (CAR)-modified autologous T cells redirected against mesothelin (CART-meso) in patients with malignant pleural mesothelioma, ovarian carcinoma, and pancreatic ductal adenocarcinoma. Fifteen patients with chemotherapy-refractory cancer (n = 5 per indication) were treated with a single CART-meso cell infusion. CART-meso cells were engineered by lentiviral transduction with a construct composed of the anti-mesothelin single-chain variable fragment derived from the mouse monoclonal antibody SS1 fused to intracellular signaling domains of 4-1BB and CD3zeta. Patients received 1-3 × 107 or 1-3 × 108 CART-meso cells/m2 with or without 1.5 g/m2 cyclophosphamide. Lentiviral-transduced CART-meso cells were well tolerated; one dose-limiting toxicity (grade 4, sepsis) occurred at 1-3 × 107/m2 CART-meso without cyclophosphamide. The best overall response was stable disease (11/15 patients). CART-meso cells expanded in the blood and reached peak levels by days 6-14 but persisted transiently. Cyclophosphamide pre-treatment enhanced CART-meso expansion but did not improve persistence beyond 28 days. CART-meso DNA was detected in 7/10 tumor biopsies. Human anti-chimeric antibodies (HACA) were detected in the blood of 8/14 patients. CART-meso cells were well tolerated and expanded in the blood of all patients but showed limited clinical activity. Studies evaluating a fully human anti-mesothelin CAR are ongoing.
Insights
This study found that chimeric antigen receptor T-cells targeting mesothelin (CART-meso) were safe and expanded in patients with difficult cancers. However, clinical activity was limited, suggesting further research is needed.
Area of Science:
- Oncology
- Immunotherapy
- Cell Therapy
Background:
- Mesothelin is a tumor-associated antigen overexpressed in malignant pleural mesothelioma, ovarian, and pancreatic cancers.
- Chimeric antigen receptor (CAR) T-cell therapy offers a promising approach for targeting solid tumors.
Purpose of the Study:
- To investigate the safety and activity of lentiviral-transduced anti-mesothelin CAR T-cells (CART-meso) in patients with advanced solid tumors.
- To assess CART-meso cell expansion, persistence, and clinical response in chemotherapy-refractory cancers.
Main Methods:
- Phase I clinical trial involving 15 patients with malignant pleural mesothelioma, ovarian carcinoma, or pancreatic ductal adenocarcinoma.
- Patients received a single infusion of CART-meso cells engineered with a lentiviral vector encoding an anti-mesothelin CAR.
- Doses ranged from 1-3 × 10^7 to 1-3 × 10^8 cells/m², with or without cyclophosphamide pre-treatment.
Main Results:
- CART-meso cells were generally well-tolerated, with one dose-limiting toxicity (sepsis).
- All patients showed CART-meso cell expansion in blood, peaking by days 6-14, but with transient persistence.
- Stable disease was the best overall response observed in 11 out of 15 patients; clinical activity was limited.
Conclusions:
- Lentiviral-transduced CART-meso cells demonstrate acceptable safety and in vivo expansion in patients with mesothelin-expressing cancers.
- Transient persistence and limited clinical efficacy were observed, highlighting the need for further optimization.
- Ongoing studies are exploring fully human anti-mesothelin CAR constructs to improve therapeutic outcomes.
Related Concept Videos
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Transducer Mechanism: G Protein–Coupled Receptors
GPCRs are also called heptahelical,...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Diversity of Antigen Receptors
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Internal Receptors
Phase Diagrams

